7月14日，10x Genomics盘中上涨5.27%，报44.15美元/股，成交额2118.27万美元。
消息面上，美银证券（BofA Securities）将10x Genomics目标价从30美元大幅上调至46美元，上调幅度达53%，显著高于市场一致目标价25.77美元。该调整反映出机构对公司基本面改善的认可。
基本面方面，公司一季度EPS为-0.10美元，大幅好于市场预期的-0.30美元；营收1.51亿美元亦超预期。此外，公司近期完成对Proteintech Genomics的收购以拓展蛋白组学能力，并与克利夫兰诊所建立膀胱癌诊断合作，业务布局持续拓宽。公司全年营收指引为6.00亿至6.25亿美元，亏损持续收窄趋势明确。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.